Oncology
Stories
-
FDA expands Anktiva indication to high-grade papillary bladder cancer
On October 14, 2026, the FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) with BCG for BCG-unresponsive non-muscle invasive bladder cancer with high-grade papillary-only tumors. The agency extrapolated from earlier data in patients with carcinoma in situ.
-
Roche posts IMpower030 results: atezolizumab before surgery in resectable lung cancer
Hoffmann-La Roche posted results for the Phase 3 IMpower030 trial on October 9, 2026. In the Stage IIB-IIIB wild-type group, median event-free survival was 34.92 months on placebo and 62.78 months on atezolizumab, both plus chemotherapy.
-
FDA approves tucatinib with trastuzumab and pertuzumab for HER2-positive breast cancer
On October 7, 2026, the FDA approved Tukysa with trastuzumab and pertuzumab as maintenance treatment for HER2-positive breast cancer. The FDA said median progression-free survival was 24.9 months with tucatinib and 16.3 months with placebo.
-
FDA approves atezolizumab with chemotherapy for Stage III dMMR colon cancer
On October 8, 2026, the FDA approved atezolizumab with a fluoropyrimidine and oxaliplatin for adjuvant treatment of Stage III dMMR colon cancer. The FDA said the ATOMIC trial showed a hazard ratio of 0.50 for disease-free survival.